News | August 12, 2007

Removing Large Thrombus Prior to DES Implant Improves Outcomes

August 13, 2007 – A study published in the Journal of the American College of Cardiology showed that when AngioJet thrombectomy is used to remove large thrombus before placement of a drug-eluting stent (DES), it is associated with significantly lower rates of subsequent death, repeat heart attack and stent thrombosis.

The work is authored by Dr. George Sianos and colleagues at the ThoraxCenter in Rotterdam, the Netherlands, and appears in the Journal of the American College of cardiology (JACC), volume 50, number 7, dated August 14, 2007. The publication can be viewed on-line at http://content.onlinejacc.org.

Dr. Sianos analyzed 812 consecutive heart attack patients receiving a DES. Twenty-eight percent of the patients had large thrombus that complicated their treatment. These patients had a much higher incidence of serious adverse events out to two years after treatment, compared to the other patients who did not have large thrombus. The important exceptions were patients whose initial large thrombus was removed with AngioJet thrombectomy before stenting: these patients had a low incidence of serious adverse outcomes, similar to those patients with little or no thrombus to begin with. AngioJet thrombectomy was the single most powerful statistical predictor of a good clinical outcome in such patients.

Said Robert G. Dutcher, CEO of Possis Medical, Inc., "This important study demonstrates that unresolved large thrombus is common in acute coronary cases, and that placing a DES without first removing the thrombus contributes significantly to later life-threatening complications, including stent thrombosis. AngioJet thrombectomy lowers this risk by safely converting a clotted vessel that is at high risk for worse clinical outcomes into an un-clotted, low-risk vessel that can be successfully stented. We believe these results offer an important perspective that addresses some of the current uncertainty regarding DES use in higher-risk settings."

According to Dutcher, Dr. Sianos presented these key results at several important medical meetings in the last year, including the October 2006 Transcatheter Cardiovascular Therapeutics Conference in Washington D.C., and the November 2006 annual meeting of the American Heart Association in Chicago.

"Publication in the JACC, a very prestigious peer-reviewed journal, significantly increases the visibility of Dr. Sianos' results to the entire cardiology community. We believe this will have a favorable effect on the treatment choices made by the interventionalists who treat these seriously ill patients," concluded Dutcher.

For more information: http://content.onlinejacc.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome
News | Deep Vein Thrombosis| July 07, 2017
BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th...
Sponsored Content | Videos | Venous Therapies| June 27, 2017
This video, provided by Ekos, demonstrates the EkoSonic endovascular System thrombolytic system to treat deep vein th
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Overlay Init